No Relief In Sight For Future Of OTC Asthma Products
This article was originally published in The Tan Sheet
Executive Summary
The slated removal of OTC epinephrine inhalers from the market in 28 months raises questions about whether affordable alternatives will be available and whether FDA would approve another nonprescription asthma drug
You may also be interested in...
Armstrong Says FDA "Assured" OTC Access Of Reformulated Primatene Mist
Armstrong Pharmaceuticals says FDA "assured" the firm that it can sell a proposed reformulated epinephrine inhaler OTC, if approved, despite opponents who say asthma relief is an inappropriate self-medication indication